Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115204 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Binglei Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cancer-Associated Fibroblasts, Collagen, Membrane Proteins. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Urachal carcinoma is a rare and aggressive malignancy with poor responsiveness to immune checkpoint inhibitors and limited therapeutic options. In this study, we evaluated the expression of fibroblast activation protein (FAP) and collagen deposition in 29 urachal carcinoma specimens using immunohistochemistry and Masson trichrome staining, and assessed their relationship with clinicopathological features and drug response. FAP was universally expressed in cancer-associated fibroblasts (CAFs), with high levels correlating with advanced stage and lymph node metastasis. Collagen fibers were abundant in both intratumoral and peritumoral regions, and PD-L1 positivity was rare (3.4 %). All patients receiving PD-1 inhibitors exhibited disease progression. Patient-derived organoid models demonstrated broad resistance to chemotherapy and targeted agents, consistent with clinical outcomes. Although mechanistic validation was not performed, the spatial co-enrichment of FAP+ CAFs and collagen supports a stromal-mediated immune exclusion model. These findings highlight the potential of stromal reprogramming strategies as therapeutic targets in urachal carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Ce…
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China; Department of Pathology, Sun Yat-Sen University Cancer…
Zitieren
APA
Ma, B., Ma, C., Long, X., & Jiang, L. (2025). Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115204
Vancouver
Ma B, Ma C, Long X, Jiang L. Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115204
BibTeX
@article{Ma2025,
author = {Ma, Binglei and Ma, Chao and Long, Xingbo and Jiang, Lijuan},
title = {Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115204}
}
EUVIMED